Evidence map›Paper›PMID 24405716›Full record

ArticleMolecular neurodegeneration2014

Amyloid peptides ABri and ADan show differential neurotoxicity in transgenic Drosophila models of familial British and Danish dementia.

María S Marcora, Agata C Fernández-Gamba, Luz A Avendaño, Cecilia Rotondaro, Osvaldo L Podhajcer, Rubén Vidal, Laura Morelli, María F Ceriani, Eduardo M Castaño

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Massive mutagenesis reveals an incomplete amyloid motif in Bri2 that turns amyloidogenic upon C-terminal extension.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Glial Draper Rescues Aβ Toxicity in aThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2017
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

María S Marcora
Agata C Fernández-Gamba
Luz A Avendaño
Cecilia Rotondaro
Osvaldo L Podhajcer
Rubén Vidal
Laura Morelli
María F Ceriani
Eduardo M CastañoFrom Fundación Instituto Leloir, Av, Patricias Argentinas 435, Buenos Aires C1405BWE, Argentina. ecastano@leloir.org.ar.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARFundación Instituto Leloir · ARIndiana University School of Medicine

Funding

Ferritin Induced NeurodegenerationR01NS050227 · NINDS · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI VIDAL, RUBEN · 2005 to 2015
$3.1M
Animal models to study iron homeostasisR21NS063056 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI VIDAL, RUBEN · 2009 to 2010
$411k
NINDS NIH HHS NS050227NINDS NIH HHS NS063056NINDS NIH HHS R01 NS050227
6 · The paper itself

Abstract

backgroundFamilial British and Familial Danish dementias (FBD and FDD, respectively) are associated with mutations in the BRI2 gene. Processing of the mutated BRI2 protein leads to the accumulation in the brain of the 34-mer amyloid Bri (ABri) and amyloid Dan (ADan) peptides, accompanied by neurofibrillary tangles. Recently, transgenic mice successfully reproduced different aspects of FDD, while modeling of FBD in vivo has been more difficult. In this work we have modeled FBD and FDD in Drosophila and tested the hypothesis that ABri and ADan are differentially neurotoxic.

resultsBy using site-directed insertion, we generated transgenic lines carrying ABri, ADan, Bri2-23 (the normal product of wild-type BRI2 processing) and amyloid-β (Aβ) 1-42 as a well-characterized neurotoxic peptide, alone or with a His-tag. Therefore, we avoided random insertion effects and were able to compare levels of accumulation accurately. Peptides were expressed with the GAL4-Upstream Activating Sequence (UAS) system using specific drivers. Despite low levels of expression, toxicity in the eye was characterized by mild disorganization of ommatidia and amyloid peptides accumulation. The highest toxicity was seen for ADan, followed by Aβ42 and ABri. Pan-neuronal expression in the CNS revealed an age-dependent toxicity of amyloid peptides as determined by the ability of flies to climb in a geotaxis paradigm when compared to Bri2-23. This effect was stronger for ADan, detected at 7 days post-eclosion, and followed by ABri and Aβ42, whose toxicity became evident after 15 and 21 days, respectively. Histological analysis showed mild vacuolization and thioflavine-S-negative deposits of amyloid peptides. In contrast, the over-expression of amyloid peptides in the specific subset of lateral neurons that control circadian locomotor activity showed no toxicity.

conclusionsOur results support the differential neurotoxicity of ADan and ABri in the Drosophila eye and CNS at low expression levels. Such differences may be partially attributed to rates of aggregation and accumulation. In the CNS, both peptides appear to be more neurotoxic than wild-type Aβ42. These Drosophila models will allow a systematic and unambiguous comparison of differences and similarities in the mechanisms of toxicity of diverse amyloid peptides associated with dementia.

Indexed as

CataractCerebellar AtaxiaCerebral Amyloid Angiopathy, FamilialDeafnessDementiaDisease Models, AnimalAdaptor Proteins, Signal TransducingAmyloid Neuropathies, FamilialAnimalsAnimals, Genetically ModifiedDrosophila melanogasterMembrane GlycoproteinsAdaptor Proteins, Signal TransducingITM2B protein, humanMembrane Glycoproteins

Identifiers

PMID24405716
PMCPMC3898387
OpenAlexW2144438675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.